GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Er Therapeutics PNGM · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2010

Net income

−$426,953

FY2010FY2010

Free cash flow

−$229,500

FY2010FY2010

Shareholders' equity

−$112,369

FY2010FY2010

Income statement

Fiscal years

FY2010
Operating income−$311,297
Net income−$426,953
Diluted earnings per share-0.02

Balance sheet

At each fiscal year end

FY2010
Total assets$423,595
Total liabilities$535,964
Shareholders' equity−$112,369
Shares outstanding26m

Cash flow

Fiscal years

FY2010
Cash from operations−$161,425
Capital spending−$68,075
Free cash flow−$229,500

Latest quarters

By quarter end

Aug 2012May 2012Feb 2012Aug 2011May 2011Feb 2011Nov 2010Aug 2010
Operating income−$36,800−$42,900−$39,800−$426,106−$113,134−$52,737−$78,294−$160,000
Net income−$40,900−$42,900−$39,800−$433,529−$7,361−$57,109−$100,092−$150,000
Diluted earnings per share-0.00-0.00-0.00-0.01-0.00-0.00-0.00—
Total assets$374,000$373,200—$389,165$398,576$408,282$423,595$490,000
Cash and short-term investments$4,100$1,000—————$30,000
Debt$268,700$209,300—————$310,000
Shareholders' equity−$455,500−$414,500—−$255,368−$176,839−$169,478−$112,369−$120,000

Growth per year

Compound annual rate

3 years5 years10 years
Operating income44.6%——
Net income57.9%——

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return100%0%0%0%998%931%19848%33037%45400%416%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 3-for-1 split · 13 Apr 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.